EP1341553A4 - DAMPED ANTI-CD28 ANTIBODIES AND THEIR USE - Google Patents

DAMPED ANTI-CD28 ANTIBODIES AND THEIR USE

Info

Publication number
EP1341553A4
EP1341553A4 EP01995504A EP01995504A EP1341553A4 EP 1341553 A4 EP1341553 A4 EP 1341553A4 EP 01995504 A EP01995504 A EP 01995504A EP 01995504 A EP01995504 A EP 01995504A EP 1341553 A4 EP1341553 A4 EP 1341553A4
Authority
EP
European Patent Office
Prior art keywords
silensed
antibodies
silensed anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01995504A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1341553A1 (en
Inventor
J Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobu Seki
Hirotsugu Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP1341553A1 publication Critical patent/EP1341553A1/en
Publication of EP1341553A4 publication Critical patent/EP1341553A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP01995504A 2000-12-14 2001-12-14 DAMPED ANTI-CD28 ANTIBODIES AND THEIR USE Withdrawn EP1341553A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US255155P 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number Publication Date
EP1341553A1 EP1341553A1 (en) 2003-09-10
EP1341553A4 true EP1341553A4 (en) 2004-07-28

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01995504A Withdrawn EP1341553A4 (en) 2000-12-14 2001-12-14 DAMPED ANTI-CD28 ANTIBODIES AND THEIR USE

Country Status (18)

Country Link
EP (1) EP1341553A4 (cs)
JP (1) JP2004515243A (cs)
KR (1) KR20040020866A (cs)
CN (1) CN1272345C (cs)
AR (1) AR031924A1 (cs)
AU (2) AU2002226086C1 (cs)
BR (1) BR0116686A (cs)
CA (1) CA2432736A1 (cs)
CZ (1) CZ20031909A3 (cs)
HU (1) HUP0400697A3 (cs)
IL (1) IL156262A0 (cs)
MX (1) MXPA03005327A (cs)
NO (1) NO20032542L (cs)
NZ (1) NZ526569A (cs)
PL (1) PL363239A1 (cs)
RU (1) RU2261723C2 (cs)
WO (1) WO2002047721A1 (cs)
ZA (1) ZA200305384B (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20220153845A1 (en) * 2019-03-14 2022-05-19 Biond Biologics Ltd. A method for immunosuppression
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEGRE M-L ET AL: "IMMUNOMODULATION OF TRANSPLANT REJECTION USING MONOCLONAL ANTIBODIES AND SOLUBLE RECEPTORS", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 40, no. 1, January 1995 (1995-01-01), pages 58 - 64, XP002912150, ISSN: 0163-2116 *
CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE C-H2 DOMAIN AND IS MODULATED BY THE HINGE REGION", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, no. 6, 1991, pages 1483 - 1491, XP002278409, ISSN: 0022-1007 *
COLE M S ET AL: "Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, no. 7, 1 October 1997 (1997-10-01), pages 3613 - 3621, XP002226664, ISSN: 0022-1767 *
KRUMMERL M F ET AL: "SUPERANTIGEN RESPONSES AND CO-STIMULATION: CD28 AND CTLA-4 HAVE OPPOSING EFFECTS ON T CELL EXPANSION IN VITRO AND IN VIVO", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 8, no. 4, 1996, pages 519 - 523, XP002908623, ISSN: 0953-8178 *
LANIER L L ET AL: "CD80 (B7) AND CD86 (B70) PROVIDE SIMILAR COSTIMULATORY SIGNALS FOR T CELL PROLIFERATION, CYTOKINE PRODUCTION, AND GENERATION OF CTL", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 97 - 105, XP002018932, ISSN: 0022-1767 *
MAN SUNG CO: "CHIMERIC AND HUMANIZED ANTIBODIES WITH SPECIFICITY FOR THE CD33 ANTIGEN1", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 148, no. 4, 15 February 1992 (1992-02-15), pages 1149 - 1154, XP000368716, ISSN: 0022-1767 *
See also references of WO0247721A1 *
TAN P ET AL: "Humanization of an anti-CD28 antibody using germline human antibody sequences", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 96, no. 11 PART 1, November 2000 (2000-11-01), pages 31A, XP002177441, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
HUP0400697A3 (en) 2007-05-02
NO20032542L (no) 2003-08-07
CZ20031909A3 (cs) 2003-11-12
KR20040020866A (ko) 2004-03-09
RU2261723C2 (ru) 2005-10-10
ZA200305384B (en) 2004-10-11
EP1341553A1 (en) 2003-09-10
BR0116686A (pt) 2003-12-30
WO2002047721A1 (en) 2002-06-20
AU2608602A (en) 2002-06-24
MXPA03005327A (es) 2004-12-03
CA2432736A1 (en) 2002-06-20
AU2002226086C1 (en) 2006-03-09
PL363239A1 (en) 2004-11-15
CN1489473A (zh) 2004-04-14
HUP0400697A2 (hu) 2004-06-28
NO20032542D0 (no) 2003-06-05
NZ526569A (en) 2005-07-29
AU2002226086B2 (en) 2005-08-25
JP2004515243A (ja) 2004-05-27
RU2003121231A (ru) 2005-02-10
IL156262A0 (en) 2004-01-04
CN1272345C (zh) 2006-08-30
AR031924A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
HK1208705A1 (en) Multivalent antibodies and uses therefor
TWI316088B (en) Anti-tnf alpha antibodies and their uses
GB0029360D0 (en) Humanised antibodies and uses thereof
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
GB9927332D0 (en) Novel antibody and uses thereof
HUP0400697A3 (en) Silensed anti-cd28 antibodies and use thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
GB0007333D0 (en) Novel compounds and their manufacture and use
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) ANTIBODY AND ITS USE
IL166063A0 (en) Antibodies and uses thereof
GB0026134D0 (en) Peptides and their use
EP1302770A4 (en) PARTICLE MARKING PROTEIN AND IMMUNO-CHROMATOGRAPHER USING THE SAME
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
EP1627888A4 (en) ANTIBODY AND ITS USE
EP1437367A4 (en) ANTIBODIES AND ITS USE
GB0003527D0 (en) Antibodies
GB0005071D0 (en) Antibodies
GB0227080D0 (en) Antibodies and uses thereof
GB0002559D0 (en) Virulencegene and protein and their use
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DIN1 Information on inventor provided before grant (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SEKI, NOBU,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: HIGASHI, YASUYUKI,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: TAMURA, KOUICHI,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: VASQUEZ, MAXIMILIANO

Inventor name: HINTON, PAUL

Inventor name: TSO, J. YUN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: UEDA, HIROTSUGU,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: SEKI, NOBU,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: HIGASHI, YASUYUKI,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: TAMURA, KOUICHI,C/O FUJISAWA PHARMACEUT.CO.,LTD

Inventor name: VASQUEZ, MAXIMILIANO

Inventor name: HINTON, PAUL

Inventor name: TSO, J. YUN

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/00 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 12N 15/13 B

Ipc: 7C 07K 16/28 B

Ipc: 7A 61K 39/395 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040614

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

17Q First examination report despatched

Effective date: 20060215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070623